Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease

被引：32

作者：

Nutt, JG ^{[1
]}

机构：

[1] Oregon Hlth Sci Univ, Sch Med, Dept Neurol, Portland, OR 97201 USA

[2] Oregon Hlth Sci Univ, Sch Med, Dept Physiol, Portland, OR 97201 USA

[3] Oregon Hlth Sci Univ, Sch Med, Dept Pharmacol, Portland, OR 97201 USA

来源：

LANCET | 1998年 / 351卷 / 9111期

关键词：

D O I：

10.1016/S0140-6736(05)79311-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1221 / 1222

页数：2

共 13 条

[1] Tolcapone, bromocriptine, and Parkinson's disease [J].

Agid, Y ;

Destee, A ;

Durif, F ;

Montastruc, JL ;

Pollak, P .

LANCET, 1997, 350 (9079) :712-713

[2] Catechol-O-methyltransferase inhibition with tolcapone reduces the ''wearing off'' phenomenon and levodopa requirements in fluctuating parkinsonian patients [J].

Baas, H ;

Beiske, AG ;

Ghika, J ;

Jackson, M ;

Oertel, WH ;

Poewe, W ;

Ransmayr, G ;

Auff, E ;

Volc, D ;

Dupont, E ;

Mikkelsen, B ;

Wermuth, L ;

WommPetersen, J ;

Benecke, R ;

Eichhom, T ;

Kolbe, H ;

Oertel, W ;

Schimrigk, K ;

Olsson, JE ;

Palhagen, S ;

Burgunder, JM ;

Ghika, A ;

Regli, F ;

Steck, A ;

Medcalf, P .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1997, 63 (04) :421-428

[3]

HAUSER RA, IN PRESS MOV DISORD

[4] Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly [J].

Jorga, KM ;

Sedek, G ;

Fotteler, B ;

Zurcher, G ;

Nielsen, T ;

Aitken, JW .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (03) :300-310

[5]

Kieburtz K, 1997, ANN NEUROL, V42, P747

[6] Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial [J].

Kurth, MC ;

Adler, CH ;

StHilaire, M ;

Singer, C ;

Waters, C ;

LeWitt, P ;

Chernik, DA ;

Dorflinger, EE ;

Yoo, K ;

Lieberman, AN ;

Brewer, M ;

SaintHilaire, M ;

Pery, LM ;

Thomas, C ;

Turpin, L ;

OBrien, CF ;

Seeberger, LC ;

Duncan, KL ;

Caviness, JN ;

Douglas, M ;

Wheeler, K ;

Riley, D ;

Rainey, P ;

Tanner, CM ;

Kelker, K ;

Lewis, P ;

Trosch, RM ;

Mistura, KL ;

Montgomery, EB ;

Lindsey, B ;

Weiner, W ;

Shulman, LM ;

Sheldon, C ;

Waters, CH ;

Welsh, M ;

Trugman, JM ;

Landow, ER ;

Pedder, SCJ ;

Shimon, GS ;

Magni, G .

NEUROLOGY, 1997, 48 (01) :81-87

[7]

Mannisto P T, 1992, Prog Drug Res, V39, P291

[8] 3-O-METHYLDOPA AND THE RESPONSE TO LEVODOPA IN PARKINSONS-DISEASE [J].

NUTT, JG ;

WOODWARD, WR ;

GANCHER, ST ;

MERRICK, D .

ANNALS OF NEUROLOGY, 1987, 21 (06) :584-588

[9] EFFECT OF PERIPHERAL CATECHOL-O-METHYLTRANSFERASE INHIBITION ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF LEVODOPA IN PARKINSONIAN-PATIENTS [J].

NUTT, JG ;

WOODWARD, WR ;

BECKNER, RM ;

STONE, CK ;

BERGGREN, K ;

CARTER, JH ;

GANCHER, ST ;

HAMMERSTAD, JP ;

GORDIN, A .

NEUROLOGY, 1994, 44 (05) :913-919

[10] Tolcapone improves motor function in parkinsonian patients with the ''wearing-off'' phenomenon: A double-blind, placebo-controlled, multicenter trial [J].

Rajput, AH ;

Martin, W ;

SaintHilaire, MH ;

Dorflinger, E ;

Pedder, S .

NEUROLOGY, 1997, 49 (04) :1066-1071

← 1 2 →